Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital.
D001085:Arabinofuranosylcytosine Triphosphate / Q000378:metabolism; D002869:Chromosome Aberrations; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004351:Drug Resistance; D006207:Half-Life; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D007951:Leukemia, Myeloid / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D011379:Prognosis; D013997:Time Factors
D003561:Cytarabine; D001085:Arabinofuranosylcytosine Triphosphate